Last reviewed · How we verify
cis-platinum
Cisplatin is a platinum-based chemotherapy agent that forms DNA adducts and cross-links, preventing DNA replication and transcription to induce cancer cell death.
Cisplatin is a platinum-based chemotherapy agent that forms DNA adducts and cross-links, preventing DNA replication and transcription to induce cancer cell death. Used for Metastatic testicular cancer, Metastatic ovarian cancer, Advanced bladder cancer.
At a glance
| Generic name | cis-platinum |
|---|---|
| Also known as | Cisplatin, Cisplantin Injection, cisplatin, Platinol |
| Sponsor | Peking University Third Hospital |
| Drug class | Platinum-based alkylating agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Cisplatin enters cancer cells and undergoes aquation to form reactive platinum species that bind to purine bases in DNA, creating intrastrand and interstrand cross-links. These DNA lesions trigger apoptosis and cell cycle arrest, leading to cancer cell death. The drug is non-cell-cycle specific and effective against rapidly dividing cells.
Approved indications
- Metastatic testicular cancer
- Metastatic ovarian cancer
- Advanced bladder cancer
- Head and neck cancer
- Lung cancer
- Gastric cancer
Common side effects
- Nephrotoxicity
- Ototoxicity
- Nausea and vomiting
- Myelosuppression
- Peripheral neuropathy
- Electrolyte abnormalities (hypomagnesemia, hypokalemia)
Key clinical trials
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer (PHASE2)
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cis-platinum CI brief — competitive landscape report
- cis-platinum updates RSS · CI watch RSS
- Peking University Third Hospital portfolio CI